• 中药标准品生产商,产品定制服务
  • 白术内酯I; 苍术内酯I

    Atractylenolide I

    白术内酯I; 苍术内酯I
    产品编号 CFN99944
    CAS编号 73069-13-3
    分子式 = 分子量 C15H18O2 = 230.30
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Sesquiterpenoids
    植物来源 The rhizomes of Atractylodes macrocephala Koidz.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    白术内酯I; 苍术内酯I CFN99944 73069-13-3 10mg QQ客服:2932563308
    白术内酯I; 苍术内酯I CFN99944 73069-13-3 20mg QQ客服:2932563308
    白术内酯I; 苍术内酯I CFN99944 73069-13-3 50mg QQ客服:2932563308
    白术内酯I; 苍术内酯I CFN99944 73069-13-3 100mg QQ客服:2932563308
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • CSIRO - Agriculture Flagship (Australia)
  • National Chung Hsing University (Taiwan)
  • University of Madras (India)
  • Harvard University (USA)
  • Universidad Veracuzana (Mexico)
  • National Hellenic Research Foundation (Greece)
  • Massachusetts General Hospital (USA)
  • The Vancouver Prostate Centre (VPC) (Canada)
  • Universidad Industrial de Santander (Colombia)
  • Lodz University of Technology (Poland)
  • Chiang Mai University (Thailand)
  • Melbourne University (Australia)
  • Universiti Sains Malaysia (Malaysia)
  • University of Auckland (New Zealand)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Nat Prod Commun.2014, 9(5):679-82
  • J-STAGE2015, 249-255
  • Tumour Biol.2015, 36(12):9385-93
  • Acta Pharm Sin B.2015, 5(4):323-9.
  • Asian J Beauty Cosmetol2016, 14(3):249-257
  • Phytochem Anal.2016, 27(5):296-303
  • Am J Chin Med.2016, 44(8):1719-1735
  • Pharmacognosy Magazine2017, 13(52):868-874
  • J Ethnopharmacol.2017, 206:327-336
  • Int J Biol Macromol.2018, 112:1093-1103
  • Int J Mol Sci.2018, 19(9):E2681
  • Phytomedicine.2018, 38:12-23
  • Front Pharmacol.2018, 9:236
  • Front Pharmacol.2018, 9:756
  • J Ethnopharmacol.2019, 235:406-414
  • Molecules.2019, 24(23):E4303
  • Exp Biol Med (Maywood).2019, 244(16):1463-1474
  • Pak J Pharm Sci.2019, 32(6):2879-2885
  • Journal of Food Hygiene and Safety2019, 34(5):413-420
  • Chinese Pharmacological Bulletin2019, 35(8):1120-1125
  • J Food Biochem.2019, 43(9):e12970
  • J Mol Histol.2019, 50(4):343-354
  • Phytomedicine.2019, 58:152893
  • ...
  • 生物活性
    Description: Atractylenolide I, a TLR4-antagonizing agent, shows a wide spectrum of pharmacological activities such as anti-inflammatory, digestion promoting,significant antitumor, and antioxidant effects. It ameliorates sepsis syndrome,liver and kidney functions by reduction of pro-inflammatory cytokines and LPS.
    Targets: TNF-α | IL Receptor | ERK | p38MAPK | TLR | NF-kB | Bcl-2/Bax | Caspase | NO | VEGFR
    In vitro:
    Immunopharmacol Immunotoxicol. 2014 Dec;36(6):420-5.
    Atractylenolide I inhibits lipopolysaccharide-induced inflammatory responses via mitogen-activated protein kinase pathways in RAW264.7 cells.[Pubmed: 25270720]
    Atractylenolide I (ATL-I) is a bioactive component of Rhizoma Atractylodis macrocephalae. Although increasing evidence shows that Atractylenolide I has an anti-inflammatory effect, the anti-inflammatory molecular mechanism of Atractylenolide I is still unknown.
    METHODS AND RESULTS:
    In this study, we investigated the effect of Atractylenolide I on cell viability by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay and the level of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) by enzyme-linked immunosorbent assay (ELISA) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Further, we examined the effect of Atractylenolide I on the activation of nuclear factor-kappaB (NF-κB) and phosphorylation of extracellular signal regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (p38) by Western blot. We also investigated the effect of Atractylenolide I on the expression of myeloid differentiation protein-2 (MD-2), CD14, complement receptor 3 (CR3), scavenger receptor class A (SR-A), toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 (MyD88). We found that Atractylenolide I showed no inhibitory effect on cell viability at concentrations ranging from 1 μM to 100 μM and markedly reduced the release of IL-6 and TNF-α at a concentrate-dependent manner. In addition, Atractylenolide I suppressed the activity of nuclear NF-κB and the phosphorylation of ERK1/2 and p38 in LPS-treated RAW264.7 cells. Further analysis showed that ATL-I inhibited the expression of MD-2, CD14, SR-A, TLR4 and MyD88, but the expression of CR3 was unaffected.
    METHODS AND RESULTS:
    These data suggest that Atractylenolide I shows an anti-inflammatory effect by inhibiting TNF-α and IL-6 production. The anti-inflammatory effects of Atractylenolide I may be associated with the inhibition of the NF-κB, ERK1/2 and p38 signaling pathways.
    Sci Rep. 2014 Jan 23;4:3840.
    Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.[Pubmed: 24452475]
    Paclitaxel, a known TLR4 ligand, leads to activation of TLR4/MyD88-dependent pathway that mediates chemoresistance and tumor progression in epithelial ovarian carcinoma (EOC). Atractylenolide I (AO-I), a novel TLR4-antagonizing agent, inhibits TLR4 signaling by interfering with the binding of LPS or paclitaxel to membrane TLR4 of human leukocytes.
    METHODS AND RESULTS:
    In this study, AO-I was found to attenuate paclitaxel-induced protein expression of IL-6, VEGF and survivin, and to enhance early apoptosis and growth inhibition in MyD88(+) EOC cells; AO-I was shown to fit into the hydrophobic pocket of human MD-2 and to partially overlap with the binding site of paclitaxel by docking simulations, suggesting that AO-I may block the MD-2-mediated TLR4/MyD88-dependent paclitaxel signaling in MyD88(+) EOC cells.
    CONCLUSIONS:
    Therefore, AO-I could significantly sensitize the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling, and that AO-I-paclitaxel combination could be a promising strategy for the treatment of EOC with a functional TLR4/MyD88/NF-κB pathway.
    In vivo:
    Pharm Biol. 2015 Apr 8:1-5.
    The protective effect of atractylenolide I on systemic inflammation in the mouse model of sepsis created by cecal ligation and puncture.[Pubmed: 25853971]
    Atractylenolide I (AT-I), an active compound isolated from Atractylodes macrocephala Koidz (Compositae), shows several pharmacological activities. Our present study is designed to investigate the protective effect of Atractylenolide I on systemic inflammation in the mouse model of sepsis created by cecal ligation and puncture (CLP), and explore the possible mechanism.
    METHODS AND RESULTS:
    Sepsis mouse model was established by CLP, and the tested dosages of Atractylenolide I were 10, 20, and 40 mg/kg (ip). Pro-inflammatory cytokines in serum (TNF-α, IL-1β and IL-6) were determined by the ELISA method; serum lipopolysaccharide (LPS) level was measured by the Limulus Amebocyte Lysate (LAL) test; white blood cells (WBC) were counted by Blood cell analyzer; contents of alanine transaminase (ALT), aspartate transarninase (AST), creatinine (Cre), and blood urea nitrogen (BUN) in serum were determined by automatic biochemistry analyzer. For survival rate tests, CLP mice were observed within 7 days, and body temperature was measured at 0, 4, 8, 12, 24, 48 and 72 h after surgery. Our results indicated that Atractylenolide I significantly increased the survival rate of mice with sepsis (p < 0.05), whereas the WBCs and levels of LPS, pro-inflammatory cytokines (TNF-α, IL-1β and IL-6), ALT, AST, Cre, and BUN decreased significantly after treatment with Atractylenolide I (p < 0.05).
    CONCLUSIONS:
    In conclusion, the Atractylenolide I ameliorates sepsis syndrome by reduction of pro-inflammatory cytokines and LPS, and provides an improvement in liver and kidney functions.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 4.3422 mL 21.7108 mL 43.4216 mL 86.8432 mL 108.5541 mL
    5 mM 0.8684 mL 4.3422 mL 8.6843 mL 17.3686 mL 21.7108 mL
    10 mM 0.4342 mL 2.1711 mL 4.3422 mL 8.6843 mL 10.8554 mL
    50 mM 0.0868 mL 0.4342 mL 0.8684 mL 1.7369 mL 2.1711 mL
    100 mM 0.0434 mL 0.2171 mL 0.4342 mL 0.8684 mL 1.0855 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    Chlorantholide C; Chlorantholide C CFN97970 1372558-35-4 C15H18O3 = 246.3 5mg QQ客服:2159513211
    Chlorantholide D; Chlorantholide D CFN97956 1253106-58-9 C15H18O4 = 262.3 5mg QQ客服:3257982914
    Chlorantholide E; Chlorantholide E CFN97969 1372558-36-5 C15H18O5 = 278.3 5mg QQ客服:2932563308
    4alpha,6alpha-Dihydroxyeudesm-11(13)-en-12,8beta-olide; 4alpha,6alpha-Dihydroxyeudesm-11(13)-en-12,8beta-olide CFN89139 35001-19-5 C15H22O4 = 266.33 5mg QQ客服:1413575084
    Wedelialactone A; Wedelialactone A CFN96439 175862-40-5 C24H34O8 = 450.53 5mg QQ客服:2932563308
    6-O-Methacryloyltrilobolide; 6-O-Methacryloyltrilobolide CFN89319 950685-51-5 C23H30O9 = 450.48 5mg QQ客服:215959384
    Wedeliatrilolactone A; Wedeliatrilolactone A CFN96438 156993-29-2 C23H32O9 = 452.49 5mg QQ客服:3257982914
    4,8-二羟基桉叶-7(11)-烯-12,8-内酯; 4,8-Dihydroxyeudesm-7(11)-en-12,8-olide CFN99348 1231208-53-9 C15H22O4 = 266.3 5mg QQ客服:2932563308
    白术内酯I; 苍术内酯I; Atractylenolide I CFN99944 73069-13-3 C15H18O2 = 230.30 20mg QQ客服:3257982914
    白术内酯II; 苍术内酯II; Atractylenolide II CFN99945 73069-14-4 C15H20O2 = 232.32 20mg QQ客服:1148253675

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产